This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New, Fully Automated BD MAX™ MRSA Assay Rapidly Identifies Patients Colonized With Deadly Superbug

BALTIMORE, July 9, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it received FDA clearance to market the BD MAX™ MRSA molecular test in the United States. The assay is performed on the fully-automated BD MAX™ System and is designed to rapidly and accurately identify patients colonized with methicillin-resistant Staphylococcus aureus (MRSA). Rapidly and accurately identifying patients enables infection control measures to be implemented faster to reduce transmission and help prevent infection in vulnerable patients.

"The BD MAX MRSA assay is an easy-to-use, cost-effective method to identify patients colonized with this deadly superbug, which may support better outcomes for the patient and a safer hospital environment," said Tom Polen, President, BD Diagnostics – Diagnostic Systems. "FDA clearance of the BD MAX MRSA test gives our customers a new level of automation to optimize MRSA surveillance testing."

According to the Institute for Healthcare Improvement, the total cost burden to the U.S. healthcare system from MRSA infections is estimated at more than $2.5 billion annually. MRSA infections primarily occur in people who have been in hospitals or other healthcare settings. MRSA can spread among patients or healthcare workers via direct contact with colonized patients and/or hospital surfaces.  Early identification of patients colonized with MRSA helps reduce the risk of transmission and infection, and helps to improve patient outcomes.

"BD MAX is an automated, bench-top molecular system designed to perform a broad range of molecular testing, offering unmatched flexibility and versatility," said Thomas Davis, M.D., Ph.D., Professor, Pathology and Laboratory Medicine at the Indiana University School of Medicine, and Pathologist with Wishard Health Services and Indiana University Health Laboratories. "As the BD MAX assay portfolio continues to grow, the walk-away automation, standardized workflow and ease-of-use of the BD MAX System will allow laboratories to increase both the menu and efficiency of molecular testing to better meet the demands of clinicians."

The BD MAX MRSA assay is the second test cleared this year by the FDA on the BD MAX System. This milestone represents further confirmation of BD's commitment to rapidly expand its menu, enabling laboratories to offer a broad range of molecular tests that meet both their current and future clinical needs.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs